Summary
Seven patients with refractory stage III ovarian carcinoma were treated with escalating doses of human recombinant interleukin 2 (rIL-2) administered via the intraperitoneal (IP) route in an attempt to establish a dose and schedule of rIL-2 suitable for prolonged outpatient IP administration. Three patients went on to receive outpatient maintenance treatment twice weekly for 2–3 months. Doses ranged from 105 to 5 × 107 U/m2. The dose found most suitable for twice weekly outpatient IP administration was 106 U/m2. Dose-limiting toxicities consisted of diarrhea resulting in hypovolemia (5 patients) fever and chills (4 patients), nausea and vomiting (1 patient), mental status changes (2 patients), and azotemia (1 patient). These side effects were not prevented by indomethacin. Significant hypotension was not observed. Pharmacokinetic studies revealed extremely high IP concentrations of IL-2 which persisted for more than 24 hours. After a dose of 106 U/m2, the IP concentrations ranged from 670 to 760 U/ml. In one patient in whom concurrent serum concentrations were determined, the IP concentrations were over 100-fold higher than serum levels. After a dose of 107 U/m2, the IP concentrations of IL-2 ranged from 8700 to 14000. Concurrent serum levels in one patient revealed IP concentrations over 500-fold higher than serum levels. There were no consistent changes in T cell surface and activation markers on mononuclear cells from peripheral blood in 3 patients tested. Natural killer cell (NK) activity in peripheral blood increased in the three patients in whom it was measured. Four of the 7 patients progressed on treatment; 3 patients remained stable. We conclude that 106 U/m2 of rIL-2 is well-tolerated when administered by the IP route and that concentrations of IL-2 well in excess of that required to enhance cell-mediated cytotoxicity in vitro persist in the IP fluid for at least 24 hours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Henney CS, Kuribayashi K, Kern DE, Gillis S: Interleukin 2 augments natural killer cell activity. Nature (London) 291:335–338, 1981
Domzig W, Stadler BM, Herberman RB: Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol 130:1970–1973, 1983
Miyosaka N, Darnell B, Baron S, Talal N: Interleukin 2 enhances natural killing of normal lymphocytes. Cell Immunol 84:154–162, 1984
Merluzzi VJ, Savage DM, Mertelsmann R, Weite K: Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cell Immunol 84:74–84, 1984
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841, 1982
Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from perpheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157:884–897, 1983
Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of the antitumor therapeutic efficacy of long term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968–980, 1982
Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159:495–507, 1984
Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science 225:1487–1489, 1984
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Laitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, White DE: A progress report on the treatment of 157 patients with advanced cancer using Lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 136:889–897, 1987
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Eng J Med 136:898–905, 1987
Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC, Rosenberg SA: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135:2865–2875, 1985
Atkins MB, Gould JA, Allegretta M, Li JJ, Dempsey RA, Rudders RA, Parkinson DR, Reichlin S, Mier JW: Phase I evaluation of recombinant interleukin 2 in patients with advanced malignant disease. J Clin Onc 4:1380–1391, 1986
Kolitz, JE, Weite K, Wong GY, Holloway K, Merluzzi VJ, Bradley EC, Konrad M, Engert A, Polivk A, Gabrilove JL, Sykora KW, Miller GA, Fiedler W, Krown S, Oettgen HF, Mertelsmann R: Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2. J Biol Resp Modif 6:412–429, 1987
Lotze MT, Custer MC, Rosenberg SA: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 121:1373–1379, 1986
Ettinghausen SE, Rosenberg SA: Immunotherapy of mouse sarcomas using lymphokine-activated killer cells: Optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46:2784–2792, 1986
Rosenberg SA, Grimm EA, McGrogan M: Biological activity of recombinant human interleukin 2 produced in E. Coli. Science 223:1412–1415, 1984.
Doyle MV, Lee MT, Fong S: Comparison of the biological activities of human recombinant interleukin-2 and native interleukin-2. J Biol Resp Modif 4:96–109, 1985
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–210, 1981
Gillis S, Ferm M, Ou W, Smith KA: T cell growth factor: parameters of production and quantitative microassay for activity. J Immunol 120:2027, 1978
Welte K, Andreeff M, Platzer E, Hollaway K, Rubin BY, Moore MAS, Mertelsmann R: Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med 160:1390–1403, 1984
Merluzzi VJ, Weite K, Savage DM, Last-Barney K, Mertelsmann R: Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol 131:806–808, 1983
Best RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC: Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43:1395–1401, 1983
Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zighelboim J, Bast RC: Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol 152:1003–1010, 1985
Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettingen LM, Lagasse LD, Bonnem EM, Spiegel RJ, Zighelboim J: Intraperitoneal recombinant alpha-interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Cancer Res 45:4447–4453, 1985
Dedrick RL, Myers CE, Bungay PM, DeVita VT: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11, 1978
Bradley EC, Doyle M, de Grant S, Damle NK, Doyle LV, Rudolph AR, Issell BF: LAK induction in vivo in patients treated with recombinant interleukin-2 may be necessary for tumor regression. Proc Amer Assoc Cancer Res 28:405, 1987 (Abstr)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chapman, P.B., Kolitz, J.E., Hakes, T.B. et al. A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs 6, 179–188 (1988). https://doi.org/10.1007/BF00175395
Issue Date:
DOI: https://doi.org/10.1007/BF00175395